FDA’s CBER director says US will ‘never’ have China- or Australia-style system, wants one rare disease package
Karim Mikhail told Cell & Gene Meeting on the Mesa the FDA wants eventually to bring its separate rare disease efforts into one package, and set out how the Expedited IND Pilot is meant to speed up first-in-human trials.